Authors
Latest:
Dr Bansal on Outpatient Administration With Axi-Cel and Brexu-Cel in R/R NHLRadhika Bansal, MBBS, discusses outpatient administration of axi-cel and brexu-cel in relapsed/refractory non-Hodgkin lymphoma.
Latest:
Dr. O’Regan on the Development of Oral SERDs in Breast CancerRuth M. O’Regan, MD, discusses the development of oral selective estrogen receptor degraders in hormone receptor–positive breast cancer.
Latest:
Overcoming Barriers to Molecular Testing in NSCLC With Multidisciplinary CareA brief discussion on key barriers to molecular testing in non–small cell lung cancer and how multidisciplinary care plays a role in addressing these hurdles.
Latest:
Dr Muzaffar on the Evaluation of FLX475 Plus Pembrolizumab in HNSCCJameel Muzaffar, MD, discusses a study of FLX475 plus pembrolizumab in patients with head and neck squamous cell carcinoma.
Latest:
What’s Coming Next in Relapsed/Refractory Multiple MyelomaKey opinion leaders remark about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.
Latest:
Dr. Boutros on the Utility of Genetic Testing in Prostate CancerPaul C. Boutros, PhD, MBA, discusses the utility of genetic testing in prostate cancer.
Latest:
Dr Iglesia on the Potential Role for Disease Etiology in Frontline HCC Treatment SelectionMichael Iglesia, MD, PhD, discusses the potential role of disease etiology in frontline HCC treatment decision-making.
Latest:
Dr Westbrook on the Potential Use of ccRCC Therapies in Non-ccRCCThomas Westbrook, MD, discusses the investigation of approved ccRCC treatments in patients with non-ccRCC.
Latest:
Dr. Uy on the Efficacy Findings from a Phase 1/2 Trial in R/R AMLGeoffrey L. Uy, MD, discusses the efficacy findings from a phase 1/2 trial in relapsed/refractory acute myeloid leukemia.
Latest:
Closing Thoughts on the MDS Treatment LandscapeFollowing its comprehensive discussion on the treatment of MDS, the expert panel concludes with thoughts on the overall treatment landscape.
Latest:
Dr. Markowski on the Evaluation of Sabizabulin in mCRPCMark C. Markowski, MD, PhD, discusses the evaluation of sabizabulin in a phase 1b/2 trial in metastatic castration-resistant prostate cancer.
Latest:
Dr. Ghodoussipour on Trials of Cytoreductive Surgery in Metastatic RCC and Prostate CancerSaum Ghodoussipour, MD, discusses ongoing trials in renal cell carcinoma and prostate cancer.
Latest:
Treatment Option for Adult Patients with 3L+ Relapsed or Refractory Diffuse Large B-Cell LymphomaMany people living with diffuse large B-cell lymphoma (DLBCL) continue to experience significant treatment challenges. Genmab and AbbVie discuss the current DLBCL treatment landscape and an effort as part of a collaboration between the two companies for people diagnosed with relapsed or refractory DLBCL.
Latest:
Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHLPaolo Caimi, MD, discusses the rationale behind evaluating LMY-920, a novel BAFF CAR T-cell therapy, in relapsed/refractory non-Hodgkin lymphoma.
Latest:
Dr Miller on the Use of NK Cell Therapy in Hematologic MalignanciesJeffrey S. Miller, MD, discusses research with natural killer cell therapy in patients with hematologic malignancies and other cancers.
Latest:
Dr Lorusso on Key Takeaways About Relacorilant Combination Treatment in Ovarian CancerDomenica Lorusso, MD, PhD, discusses the selective glucocorticoid receptor modulator relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer.
Latest:
Dr. Sam on Sequencing Tucatinib and Trastuzumab Deruxtecan in HER2+ Breast CancerChristine Sam, MD, discusses strategies for sequencing tucatinib and fam-trastuzumab deruxtecan-nxki in the treatment of patients with HER2-positive breast cancer.
Latest:
$3.3 Million Grant to IU Researchers Aims to Increase Colorectal Cancer Screening in Rural IndianaResearchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center are addressing the low colorectal cancer screening rates in rural Indiana communities with a five-year, $3.3 million grant from the National Cancer Institute.
Latest:
Dr Asare on the Elevated Risk of Secondary Leukemias in PARP Inhibitors in Gynecologic CancersAmma Asare, MD, PhD, discusses the elevated risk of therapy-related myeloid neoplasms or secondary leukemias in gynecologic cancers after a PARP inhibitor.
Latest:
Dr. Ip on the Utility of Investigational Treatments for COVID-19 in OncologyAndrew Ip, MD, MS, discusses the utility of investigational treatments for COVID-19 in patients with cancer.
Latest:
Dr Sommerhalder on the Potential Utility of Single-Agent RMC-6291 in KRAS G12C–Mutant CRCDavid Sommerhalder, MD, discusses the potential for RMC-6291 as a single agent in KRAS G12C–mutated advanced colorectal cancer.
Latest:
Dr. Liu on Enrolling Diverse Patients in the PREEMPT-CRC Trial in CRCJulia Liu, MD, discusses enrolling diverse patients in the PREEMPT CRC trial in colorectal cancer.
Latest:
Dr Cannon on the Use of Dendritic Cell Vaccines in Ovarian CancerMartin Cannon, PhD, discusses the use of dendritic cell vaccines and immune checkpoint inhibitors in ovarian cancer.
Latest:
Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline GliomasDr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.
Latest:
Dr. Hillmen on Results With Acalabrutinib in CLLPeter Hillmen, MD, PhD, discusses results reported with acalabrutinib in patients with chronic lymphocytic leukemia, as demonstrated in a phase 3 trial.
Latest:
Dr Machtay on the Prognostic Value of Pre-Treatment Immunologic Biomarker Levels in NSCLCMitchell Machtay, MD, discusses the association between the levels of circulating immune biomarkers prior to immunotherapy and survival outcomes in patients with stage III non-small cell lung cancer.
Latest:
Dr Bhatnagar on Survival Outcomes With MRD Negativity in AMLBhavana “Tina” Bhatnagar, DO, discusses the investigation of minimal residual disease negativity in patients with acute myeloid leukemia.
.jpg?fit=crop&auto=format)
